Cargando…

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells

BACKGROUND: Standard therapy for acute promyelocytic leukaemia (APL) includes retinoic acid (all-trans retinoic acid (ATRA)), which promotes differentiation of promyelocytic blasts. Although co-administration of arsenic trioxide (ATO) with ATRA has emerged as an effective option to treat APL, the mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valenzuela, M, Glorieux, C, Stockis, J, Sid, B, Sandoval, J M, Felipe, K B, Kviecinski, M R, Verrax, J, Calderon, P Buc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150280/ https://www.ncbi.nlm.nih.gov/pubmed/25003661 http://dx.doi.org/10.1038/bjc.2014.380

Ejemplares similares

ATP7A is a novel target of retinoic acid receptor β(2) in neuroblastoma cells
por: Bohlken, A, et al.
Publicado: (2009)

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
por: Armstrong, J L, et al.
Publicado: (2005)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects
por: Liu, T, et al.
Publicado: (2013)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo
por: Armstrong, J L, et al.
Publicado: (2007)

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
por: Saha, M N, et al.
Publicado: (2014)

Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types
por: Green, S R, et al.
Publicado: (2010)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice
por: Huynh, C K, et al.
Publicado: (2006)

Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs
por: Chen, Feng, et al.
Publicado: (2017)

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
por: Fetoni, A R, et al.
Publicado: (2015)

IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma
por: Matsuoka, Yuichiro, et al.
Publicado: (2016)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid
por: Niedre, M J, et al.
Publicado: (2005)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

Harmonisation of biobanking standards in endometrial cancer research
por: Adishesh, M, et al.
Publicado: (2017)

CD44(+)CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
por: Hurt, E M, et al.
Publicado: (2008)

Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation
por: Cheng, G, et al.
Publicado: (2014)

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
por: Newman, S P, et al.
Publicado: (2007)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
por: Rasschaert, M, et al.
Publicado: (2007)

Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
por: Golding, J P, et al.
Publicado: (2013)

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
por: Day, J M, et al.
Publicado: (2009)

Elevated dietary linoleic acid increases gastric carcinoma cell invasion and metastasis in mice
por: Matsuoka, T, et al.
Publicado: (2010)

Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas
por: Separovic, D, et al.
Publicado: (2009)

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy
por: Lunt, S J, et al.
Publicado: (2010)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling
por: Boon, E M J, et al.
Publicado: (2005)

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
por: Bartlett, J M S, et al.
Publicado: (2015)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
por: Horlock, C, et al.
Publicado: (2009)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice
por: Wehenkel, M, et al.
Publicado: (2012)

Peripheral neural cell sensitivity to mTHPC-mediated photodynamic therapy in a 3D in vitro model
por: Wright, K E, et al.
Publicado: (2009)

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models
por: Jarzabek, M A, et al.
Publicado: (2014)

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
por: Veltkamp, S A, et al.
Publicado: (2006)

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
por: Yao, K, et al.
Publicado: (2005)

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
por: Patterson, M J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n408t1rlt3a0bbjp6qdrb2qe47